Clara N Curiel

Clara N Curiel

Director, Cutaneous Oncology Program
Division Chief, Dermatology
Member of the Graduate Faculty
Professor, BIO5 Institute
Professor, Medicine - (Tenure Track)
Primary Department
Department Affiliations
Contact
(520) 626-0307

Research Interest

Clara Curiel-Lewandroski, PhD, is the director of the Pigmented Lesion Clinic and Multidisciplinary Cutaneous Oncology Program, both part of the University of Arizona Cancer Center Skin Cancer Institute. She completed two research fellowships, the first in the Department of Dermatology at Harvard Medical School, and the second at the Ludwig Boltzman Institute and Immunobiology of the Skin at Miinster University in Germany. Dr. Curiel is certified by the American Board of Dermatology.Dr. Curiel-Lewandroski’s research focus is on melanoma chemoprevention, early detection of melanoma, cutaneous T cell lymphomas and skin cancer. She studied the extended use of non-steroidal anti-inflammatory drugs, particularly aspirin, and their ability to possibly decrease the risk of cutaneous medanoma (CM) development. CM is responsible for more than 77 percent of skin cancer deaths.

Publications

Krase, I. Z., Cavanaugh, K., & Curiel-Lewandrowski, C. (2016). A case of rupioid syphilis. JAAD case reports, 2(2), 141-3.
Curiel, C. N., Martinez, R., Pinto, V., Rosales, A., & Sanchez de Leon, R. (1995). Increase in cardiac output and PEEP as mechanism of pulmonary optimization. Rev Fisiol Esp, 51(1), 7-15.
Marghoob, A. A., & , I. S. (2015). Standards in Dermatologic Imaging. JAMA dermatology, 151(8), 819-21.
Curiel-Lewandrowski, C., Chen, S. C., Swetter, S. M., & , M. P. (2012). Screening and prevention measures for melanoma: is there a survival advantage?. Current oncology reports, 14(5), 458-67.

Controversy has emerged over the past decades regarding the value and impact of melanoma screening to detect early stage disease for improved prognosis. Those questioning the benefits of prevention efforts base their arguments on the absence of prospective, randomized studies demonstrating decreased melanoma mortality to justify the cost associated with screening and educational campaigns. For those in favor of melanoma screening, the lack of proven survival benefit is not a justification to abandon this approach, but rather a reflection of the lack of resources necessary to conduct a long-term trial. In 2009, the US Preventive Services Task Force (USPSTF)report did not recommend routine primary care screening for the general population given the absence of evidence. However, since the USPSTF report, a series of new studies are available, which support the potential benefit of screening and have the potential to significantly impact current policies regarding skin cancer screening, particularly for melanoma.

Richtig, E., Trapp, E. M., Avian, A., Brezinsek, H. P., Trapp, M., Egger, J. W., Kapfhammer, H. P., Rohrer, P. M., Berghold, A., Curiel-Lewandrowski, C., & Demel, U. (2015). Psychological Stress and Immunological Modulations in Early-stage Melanoma Patients. Acta dermato-venereologica, 95(6), 691-5.

Mental stress may have a negative impact on the immune state of cancer patients, in whom immunologic surveillance is essential for survival. This study investigated the immunological response of 19 patients with early-stage melanoma and a matched control group undergoing the Determination Stress Test before surgery. Cytokine and chemokine levels and lymphocyte subpopulations were measured at baseline and post-stress test time-points. Following the stress test lower levels of interleukin (IL)-6 were observed in the melanoma group compared with healthy volunteers (p = 0.044). IL-10 increased significantly in the control group 30 min after the stress test (p = 0.002) in comparison with the melanoma group (p = 0.407). CCL5/Rantes decreased significantly in the melanoma group, whereas CD16/CD56+ natural killer cells increased in both groups, with a sharp decrease below baseline after stress in the melanoma group (p = 0.001). This pilot study shows an altered immunological response to stressors in melanoma patients.